JNJ

Johnson & Johnson

Feb 19 • 04:00PM ET

246.91

+1.92 0.78 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Today, 5:05 PMJohnson & Johnson announces new Phase 1b/2 OrigAMI-4 data showing its investigational RYBREVANT FASPRO plus PD-1 inhibitor regimen achieved a 56% overall response rate in first-line recurrent or metastatic head and neck squamous cell carcinoma.

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT DIA

Scroll to Statements

Index	DJIA, S&P 500	P/E	22.35	EPS (ttm)	11.05	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	2.51%
Market Cap	595.03B	Forward P/E	19.68	EPS next Y	12.54	Insider Trans	-15.67%	Shs Float	2.41B	Perf Month	13.15%
Enterprise Value	624.26B	PEG	2.38	EPS next Q	2.69	Inst Own	75.98%	Short Float	0.81%	Perf Quarter	23.71%
Income	26.80B	P/S	6.32	EPS this Y	7.18%	Inst Trans	1.92%	Short Ratio	2.15	Perf Half Y	38.87%
Sales	94.19B	P/B	7.29	EPS next Y	8.46%	ROA	14.13%	Short Interest	19.56M	Perf YTD	19.31%
Book/sh	33.86	P/C	29.60	EPS next 5Y	8.28%	ROE	35.03%	52W High	246.35 0.23%	Perf Year	56.38%
Cash/sh	8.34	P/FCF	30.21	EPS past 3/5Y	17.88% 14.90%	ROIC	21.90%	52W Low	141.50 74.49%	Perf 3Y	53.94%
Dividend Est.	5.31 (2.15%)	EV/EBITDA	18.84	Sales past 3/5Y	5.56% 2.67%	Gross Margin	67.97%	Volatility	1.37% 1.60%	Perf 5Y	51.50%
Dividend TTM	5.14 (2.08%)	EV/Sales	6.63	EPS Y/Y TTM	90.55%	Oper. Margin	27.21%	ATR (14)	3.57	Perf 10Y	137.05%
Dividend Ex-Date	Feb 24, 2026	Quick Ratio	0.77	Sales Y/Y TTM	6.05%	Profit Margin	28.46%	RSI (14)	83.95	Recom	2.11
Dividend Gr. 3/5Y	4.92% 5.25%	Current Ratio	1.03	EPS Q/Q	48.39%	SMA20	5.43%	Beta	0.33	Target Price	238.78
Payout	46.59%	Debt/Eq	0.60	Sales Q/Q	9.07%	SMA50	12.62%	Rel Volume	0.82	Prev Close	244.99
Employees	140800	LT Debt/Eq	0.50	Earnings	Jan 21 BMO	SMA200	33.34%	Avg Volume	9.11M	Price	246.91
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.12% 1.72%	Trades		Volume	7,474,136	Change	0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$262
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$230
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform	$203
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170

Show Previous Ratings

Today 06:30PM	Corporate giants retreat from board diversity mandates, Bloomberg reports (Investing.com)
05:00PM	RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer (PR Newswire)
02:49PM	Johnson & Johnson explores $20 billion sale of orthopedics unit, Bloomberg News reports (Reuters)
02:16PM	J&J Explores $20 Billion-Plus Sale of Orthopedics Unit (Bloomberg)
01:34PM	Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility (Fox Business)
10:15AM	Loading…
10:15AM	Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure (Zacks)
07:02AM	J&J to build $1bn US CGT manufacturing site in Pennsylvania (Pharmaceutical Technology)
Feb-18-26 11:17AM	Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues (Zacks)
10:44AM	Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory (The Wall Street Journal)
10:15AM	Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania (Business Wire)
10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
09:15AM	Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy? (24/7 Wall St.)
09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:30AM	RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer (PR Newswire)
05:32AM	XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500 (24/7 Wall St.)
09:21PM	Loading…
Feb-17-26 09:21PM	This State Has More Millionaires Per Capita Than Any Other (24/7 Wall St.)
04:30PM	Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer (Benzinga)
02:32PM	Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment (Benzinga)
01:26PM	This auto-parts maker is jumping on the breakup bandwagon. Here's why the stock is tanking. (MarketWatch)
11:45AM	Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner (Benzinga)
09:27AM	Beat the Market the Zacks Way: Micron Technology, Cooper Companies, Coeur Mining in Focus (Zacks)
08:57AM	AbbVie Down Since Q4 Earnings Report: How to Play the Stock (Zacks)
08:00AM	FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month (PR Newswire)
Feb-16-26 09:55AM	J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better? (Zacks)
Feb-14-26 03:41PM	Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer (Benzinga)
02:04PM	Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 (MarketBeat)
12:44PM	Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer (Insider Monkey)
Feb-13-26 04:18PM	Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial (Business Wire)
02:48PM	Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial (Reuters)
10:09AM	Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study (Insider Monkey)
09:57AM	Loading…
09:57AM	Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds? (Insider Monkey)
Feb-12-26 01:25PM	Pentair Just Paid Out: Is This Industrial Dividend Built to Last? (24/7 Wall St.)
01:04PM	Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? (24/7 Wall St.)
05:02AM	enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment (MarketBeat)
Feb-11-26 02:23PM	NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (Benzinga)
11:14AM	Should You Buy ISRG Stock Despite a 13% Fall in Three Months? (Zacks)
08:23AM	VYMs S&P Beating Dividend Survived Two Decades Without Missing a Payment (24/7 Wall St.)
08:09AM	Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? (Zacks)
07:48AM	JEPIs 8% Yield Is Impressive, But Has a Hidden Cost Most Retirees Miss (24/7 Wall St.)
Feb-10-26 04:51PM	Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. (Barrons.com)
08:32AM	Here's What Will Drive AbbVie's Top-line Growth in 2026 (Zacks)
08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
05:53AM	4 takeaways from the 2026 AF Symposium (MedTech Dive)
Feb-09-26 04:16PM	Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference (Business Wire)
03:13PM	Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion (Barrons.com)
11:45AM	Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now (Zacks)
10:46AM	5 Stocks and ETFs to Help Shield Your Portfolio During Volatility (MarketBeat)
10:00AM	Eli Lilly Stock Rises. Its Acquiring This Cell Therapy Company for $2.4 Billion. (Barrons.com)
09:53AM	Dow Jones' revolving door: What happened to 5 companies after they were dropped from the DJIA (TheStreet)
09:24AM	J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss (Zacks)
08:51AM	Banking on Yield? Heres How We Scored Dime Community Bancshares (DCOM) Dividend (24/7 Wall St.)
07:25AM	Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study (Benzinga)
04:27AM	Can reshoring deliver manufacturing sustainability benefits? (Manufacturing Dive)
Feb-08-26 12:25PM	IVVs Uninterrupted Dividend Streak Since 2000 Masks The True Income Profile (24/7 Wall St.)
Feb-07-26 10:06PM	Recession-proof Dividend King offers safe 2.2% yield (TheStreet)
12:56AM	Jim Cramer Says Stocks Like Johnson & Johnson "Simply Refuse to Quit" (Insider Monkey)
Feb-06-26 11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
10:50AM	Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs (Barchart)
10:46AM	Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study (Zacks)
09:28AM	Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic (Zacks)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-05-26 02:42PM	RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang (Insider Monkey)
11:14AM	Why Mid Cap Dividend Stocks Are Gaining an Edge Over Large Caps This Year (24/7 Wall St.)
09:55AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
03:00AM	Big Pharma CEOs set sights on massive growth in years to come (Pharma Voice)
Feb-04-26 04:47PM	Nearly 20% of S&P 500 Stocks Hit 52-Week Highs Today (The Wall Street Journal)
01:45PM	Dozens of Stocks Hitting 52-Week Highs (The Wall Street Journal)
12:28PM	AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View (Zacks)
11:25AM	Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? (Motley Fool)
10:55AM	The John Bogle Method for Building a Dividend Portfolio Under $10,000 (24/7 Wall St.)
08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)
Feb-03-26 08:21PM	Analyst Report: Johnson & Johnson (Morningstar Research)
11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
04:34AM	BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 - Here's Why (Insider Monkey)
Feb-02-26 04:34PM	Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference (Business Wire)
11:40AM	Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year (24/7 Wall St.)
10:34AM	Buy AbbVie Stock Before Q4 Earnings? Here's What to Know (Zacks)
09:51AM	Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 (Insider Monkey)
Jan-31-26 07:35PM	Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist (Motley Fool)
12:35PM	Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy? (Insider Monkey)
Jan-30-26 10:38PM	This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? (Motley Fool)
08:28AM	What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock? (Barchart)
Jan-29-26 06:32PM	US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy (Reuters)
04:06PM	1 Dividend King to Buy and Hold Through Any Market (Barchart)
12:45PM	Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results (Insider Monkey)
12:42PM	This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks (Barrons.com)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
09:41AM	PayPal downgraded, UPS upgraded: Wall Streets top analyst calls (TipRanks)
09:13AM	Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results (Zacks)
07:12AM	Johnson & Johnson Stock Rises After Morgan Stanley Upgrade (GuruFocus.com)
03:55AM	The Zacks Analyst Blog Johnson & Johnson, Netflix, Arista Networks, Omega and AXIL (Zacks)
Jan-28-26 05:02PM	Top Stock Reports for Johnson & Johnson, Netflix & Arista Networks (Zacks)
01:25PM	Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years (Motley Fool)
12:07PM	UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs (Benzinga)
11:10AM	Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance? (Zacks)
10:21AM	Texas Instruments, Circle, Johnson & Johnson: Top Analyst Calls (Yahoo Finance Video)
10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
09:39AM	PayPal downgraded, UPS upgraded: Wall Street's top analyst calls (The Fly)
07:48AM	CMS selects next batch of 15 high-cost medicines for third negotiation cycle (Pharmaceutical Technology)
06:25AM	3 Dividend Stocks to Hold for the Next 20 Years (Motley Fool)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swanson James D.	EVP, CIO	Feb 13 '26	Option Exercise	132.73	51,418	6,824,543	47,211	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Option Exercise	164.62	20,521	3,378,167	46,219	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 15 '26	Option Exercise	0.00	1,201	0	26,007	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 13 '26	Sale	243.73	41,559	10,129,312	25,020	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Sale	242.70	20,521	4,980,447	25,698	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '26	Option Exercise	0.00	1,241	0	114,613	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	120,096	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '26	Option Exercise	0.00	994	0	20,081	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '26	Option Exercise	0.00	4,012	0	20,286	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Option Exercise	126.65	64,693	8,193,223	72,347	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '26	Option Exercise	0.00	3,849	0	39,778	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '26	Option Exercise	0.00	39,242	0	51,463	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Sale	242.80	89,654	21,767,827	14,000	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 15 '26	Option Exercise	0.00	683	0	23,777	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 13 '26	Option Exercise	0.00	3,053	0	23,950	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Option Exercise	156.89	51,648	8,103,281	42,868	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '26	Option Exercise	0.00	3,196	0	13,469	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Sale	243.00	53,931	13,105,233	10,658	Feb 18 09:12 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 15 '26	Option Exercise	0.00	2,024	0	24,112	Feb 18 09:11 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	29,591	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '26	Option Exercise	0.00	3,441	0	195,396	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '26	Option Exercise	0.00	28,714	0	206,318	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Option Exercise	121.17	22,623	2,741,335	40,394	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '26	Option Exercise	0.00	2,054	0	27,217	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '26	Option Exercise	0.00	4,877	0	26,994	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Sale	244.33	22,623	5,527,506	26,769	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '26	Option Exercise	0.00	8,187	0	326,407	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '26	Option Exercise	0.00	76,523	0	351,501	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '26	Option Exercise	0.00	1,018	0	29,470	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '26	Option Exercise	0.00	9,002	0	32,452	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 17 '26	Sale	243.39	6,197	1,508,288	23,003	Feb 18 09:11 PM
Schmid Timothy	Officer	Feb 18 '26	Proposed Sale	244.33	22,623	5,527,546		Feb 18 11:14 AM
Broadhurst Vanessa	Officer	Feb 17 '26	Proposed Sale	243.39	6,197	1,508,300		Feb 17 04:10 PM
Swanson James D.	Officer	Feb 17 '26	Proposed Sale	242.70	20,521	4,980,510		Feb 17 02:52 PM
Wolk Joseph J	Officer	Feb 17 '26	Proposed Sale	242.80	89,654	21,767,965		Feb 17 02:43 PM
REED JOHN C	Officer	Feb 17 '26	Proposed Sale	243.00	53,931	13,105,233		Feb 17 12:44 PM
Swanson James D.	Officer	Feb 13 '26	Proposed Sale	243.73	41,559	10,129,246		Feb 13 02:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 06 '26	Option Exercise	101.87	15,571	1,586,218	32,460	Feb 10 09:46 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 06 '26	Option Exercise	101.87	5,625	573,019	19,744	Feb 09 07:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 06 '26	Option Exercise	101.87	38,945	3,967,327	133,226	Feb 09 07:40 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 05 '26	Option Exercise	129.51	8,921	1,155,359	21,774	Feb 06 05:46 PM
Forminard Elizabeth	Officer	Feb 05 '26	Proposed Sale	237.90	6,226	1,481,195		Feb 05 04:31 PM
Duato Joaquin	CEO and Chairman of the Board	Jan 26 '26	Sale	221.23	100,000	22,122,893	30,852	Jan 28 06:07 PM
Joaquin Duato	CEO, Chariman	Jan 26 '26	Proposed Sale	220.14	100,000	22,014,000		Jan 26 04:57 PM
MORIKIS JOHN G	Director	Nov 26 '25	Buy	206.15	1,250	257,688	1,849	Dec 01 04:15 PM
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Option Exercise	157.92	21,721	3,430,180	32,379	Oct 20 07:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Sale	192.71	21,721	4,185,793	10,658	Oct 20 07:13 PM
REED JOHN C	Officer	Oct 17 '25	Proposed Sale	192.71	21,721	4,185,794		Oct 17 10:23 AM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience